Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Varoglutamstat
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Vivoryon Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2022
Lead Product(s) : Varoglutamstat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Vivoryon Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Puerarin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Finding Evaluation of Kudzu Root Extract in Women With Menopause Symptoms
Details : Kudzu Root Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : Puerarin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JTA-004
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Recipient : Bone Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JTA-004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2020
Lead Product(s) : JTA-004
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Recipient : Bone Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KBP-042
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : KeyBioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
Details : KBP-042 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 26, 2017
Lead Product(s) : KBP-042
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : KeyBioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sprifermin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sprifermin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 08, 2013
Lead Product(s) : Sprifermin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abaloparatide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoporosis, Postmenopausal.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 29, 2012
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
